SCRIBE THERAPEUTICS INC
SCTXNASDAQTrading Snapshot
- Day Range
- $17.27 – $17.66
- 52-Week Range
- $13.50 – $39.60
- Volume (shares)
- 23,769.333
- Avg Volume (shares)
- —
- Shares Outstanding
- 16.2M
- Next Earnings
- 2026-12-02
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
SCRIBE THERAPEUTICS INC
SCTXFinancial history unavailable.
StockOtter · stockotter.spaceAbout SCRIBE THERAPEUTICS INC
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Ark Invest added to three existing positions on Monday, all of them down sharply from recent highs.
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst
Scribe Therapeutics is initiated with a buy rating, targeting the in-vivo gene therapy market for cardiometabolic diseases with lead asset STX-1150. STX-1150 aims to provide durable, reversible PCSK9 silencing for choles
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts
Scribe Therapeutics Inc. (NASDAQ: SCTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are covering the company, MarketBeat Ratings reports. One investment analy
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering witho
Scribe Therapeutics to Participate in Upcoming Investor Conferences
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed t
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More
Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that could reshape your port